Aim­ing to shed last-place rep, Eli Lil­ly touts its PhI­II pipeline and promis­es a faster game in R&D

Eli Lil­ly wants you to know that it is de­ter­mined to lose its rep as a last-place fin­ish­er in the race to get new block­busters to the mar­ket. And the phar­ma gi­ant is sig­nal­ing that the R&D group is look­ing for more drugs it can bring in to com­plete a promised surge in new drug ap­provals over the next 5 years.

Eli Lil­ly $LLY laid out its strat­e­gy for the next wave of R&D work to­day, vow­ing to hit the gas in ac­cel­er­at­ing new de­vel­op­ment ef­forts. Lil­ly ex­ecs high­light­ed their top drugs in the pipeline and al­so made a mod­est bet on STING last night, a tar­get that has come un­der a dark cloud on the can­cer side in re­cent months. 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER